Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Prostate Cancer (mCRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Looking for participantsNCT06706921
What this trial is testing

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Who this might be right for
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more
VA Greater Los Angeles Healthcare System 15
Large-scale testing (Phase 3)Active Not RecruitingNCT03574571
What this trial is testing

Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 732
Not applicableWithdrawnNCT04742972
What this trial is testing

Prostate PMSABR Study

Who this might be right for
Prostate Cancer
Darren Poon
Not applicableLooking for participantsNCT06600802
What this trial is testing

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin 120
Testing effectiveness (Phase 2)Looking for participantsNCT05393791
What this trial is testing

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Leiden University Medical Center 168
Early research (Phase 1)Looking for participantsNCT07570979
What this trial is testing

Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Looking for participantsNCT07594106
What this trial is testing

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Clear Cell Renal Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals 265
Testing effectiveness (Phase 2)WithdrawnNCT07025512
What this trial is testing

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Who this might be right for
Metastatic Castration Resistant Prostate CancerCytopeniaAnemia+1 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Not applicableStudy completedNCT02677376
What this trial is testing

Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC

Who this might be right for
Prostatic Neoplasms
University of Wisconsin, Madison 7
Testing effectiveness (Phase 2)Looking for participantsNCT07451795
What this trial is testing

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Who this might be right for
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University 66
Large-scale testing (Phase 3)Study completedNCT04676334
What this trial is testing

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Who this might be right for
Metastatic Castration-Resistant Prostate CancerOvarian CancerEpithelial Ovarian Cancer+3 more
pharmaand GmbH 34
Testing effectiveness (Phase 2)Looking for participantsNCT06582628
What this trial is testing

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

Who this might be right for
Metastatic Prostate Cancer
Fundacion Oncosur 78
Testing effectiveness (Phase 2)UnknownNCT03085966
What this trial is testing

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd. 30
Not applicableLooking for participantsNCT06514521
What this trial is testing

Post Marketing Study on Pluvicto in Korea

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals 278
Large-scale testing (Phase 3)Study completedNCT03295565
What this trial is testing

Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel

Who this might be right for
Prostate Cancer MetastaticMetastasis
The Netherlands Cancer Institute 100
Very early researchNot Yet RecruitingNCT07389187
What this trial is testing

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
mCRPC
Shanghai Changzheng Hospital 10
Testing effectiveness (Phase 2)Study completedNCT02445976
What this trial is testing

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 197
Early research (Phase 1)Looking for participantsNCT06492122
What this trial is testing

Study With [225Ac]Ac-FL-020 in mCRPC Participants

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Full-Life Technologies UK Limited 50
Not applicableLooking for participantsNCT06517719
What this trial is testing

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals 500
Next Page